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Cathepsin S inhibition combines 
control of systemic and peripheral 
pathomechanisms of autoimmune 
tissue injury
Maia Tato1, Santhosh V. Kumar1, Yajuan Liu1,2, Shrikant R. Mulay1, Solange Moll3, Bastian 
Popper4, Jonathan N. Eberhard1, Dana Thomasova1, Arne Christian Rufer5, Sabine Gruner5, 
Wolfgang Haap5, Guido Hartmann5 & Hans-Joachim Anders  1
Cathepsin(Cat)-S processing of the invariant chain-MHC-II complex inside antigen presenting cells is a 
central pathomechanism of autoimmune-diseases. Additionally, Cat-S is released by activated-myeloid 
cells and was recently described to activate protease-activated-receptor-(PAR)-2 in extracellular 
compartments. We hypothesized that Cat-S blockade targets both mechanisms and elicits synergistic 
therapeutic effects on autoimmune tissue injury. MRL-(Fas)lpr mice with spontaneous autoimmune 
tissue injury were treated with different doses of Cat-S inhibitor RO5459072, mycophenolate mofetil 
or vehicle. Further, female MRL-(Fas)lpr mice were injected with recombinant Cat-S with/without 
concomitant Cat-S or PAR-2 blockade. Cat-S blockade dose-dependently reversed aberrant systemic 
autoimmunity, e.g. plasma cytokines, activation of myeloid cells and hypergammaglobulinemia. 
Especially IgG autoantibody production was suppressed. Of note (MHC-II-independent) IgM were 
unaffected by Cat-S blockade while they were suppressed by MMF. Cat-S blockade dose-dependently 
suppressed immune-complex glomerulonephritis together with a profound and early effect on 
proteinuria, which was not shared by MMF. In fact, intravenous Cat-S injection induced severe 
glomerular endothelial injury and albuminuria, which was entirely prevented by Cat-S or PAR-2 
blockade. In-vitro studies confirm that Cat-S induces endothelial activation and injury via PAR-2. 
Therapeutic Cat-S blockade suppresses systemic and peripheral pathomechanisms of autoimmune 
tissue injury, hence, Cat-S is a promising therapeutic target in lupus nephritis.
Autoimmune diseases present in many different facets depending on the tissue distribution of the respective 
autoantigens. However, behind the variety of clinical presentations autoimmune diseases are driven by a relea-
tively homogenous activation of the innate and adaptive immune system1. Before having fully understood the 
molecular and cellular complexity of such immune responses non-specific immunosuppressants such as steroids, 
cyclophosphamide, and mycophenolate mofetil (MMF) were found to be effective in suppressing systemic symp-
toms and tissue manifestations of autoimmune disease. The non-selective nature of such drugs explains their 
broad toxicity profiles2. Thus, it remains necessary to develop more specific drugs to control autoimmune disease. 
Specific targeting of immune processes has become possible with biological drugs, some of which have proven to 
be extremely efficent in controling autoimmune diseases such as anti-TNF-α in rheumatoid arthritis and Crohn’s 
disease or anti-CD20 in rheumatoid arthritis and ANCA vasculitis. However, these drugs are less effective in 
other forms of systemic autoimmunity3, 4, probably because they may not target universal pathomechanisms of 
autoimmunity.
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A central and non-redundant element for the activation of autoantigen-specific immunity is major histocom-
patibility complex (MHC) class II-mediated autoantigen presentation5. Cathepsin-S (Cat-S) is a cysteine pro-
tease of the papain family inside lysosomal/endosomal compartments of antigen-presenting cells, such as B cells, 
macrophages and dendritic cells6. Inside the B cells and dendritic cells, Cat S is the single enzyme that cleaves 
the lip105p105; a 10-kDa fragment of the MHC-II bound invariant chain that forms the 24 amino-acid CLIP 
fragments during the assembly of the MHC class II-α and -β chains with the antigenic peptide in the lysosomal/
endosomal compartments7–13. In addition, Cat-S limits auto-reactive CD4 T cell escape from thymic selection by 
degrading auto-antigenic peptides14, hence, there is a robust rationale for Cat-S being a mediator of autoimmun-
ity. Lack of Cat-S or Cat-S inhibition was shown to suppress autoimmunity in a number of animal models such as 
autoimmune encephalitis15, collagen-related autoimmunity15, Sjögren’s syndrome16 or SLE17.
We and others recently discovered that Cat-S has an additional biological effect, i.e. the proteolytic cleavage 
of protease-activated receptor (PAR)-2 on the surface of vascular endothelial cells, a process that contributes to 
microvascular complications in diabetes mellitus18–21. Therefore, we hypothesized that Cat-S inhibition may have 
a dual therapeutic effect on vascular autoimmune tissue injury, i.e. suppression of MHC-II-dependent systemic 
autoimmunity as well as peripheral tissue protection from autoimmune vascular injury. To address this concept 
we developed a novel highly-specific Cat-S inhibitor and tested it in vivo in comparison to standard immunosup-
pression in a model of lupus-like immune complex-related vasculopathy of the kidney, i.e. lupus nephritis.
Results
Pharmacodynamics and pharmacokinetics of RO5459072 in mice. To test the functional contri-
bution of Cat-S in systemic autoimmunity we used the inhibitor RO5459072. RO5459072 is a potent and highly 
selective compound that inhibits human Cat-S with an apparent IC50 of 0.1 nM and murine Cat-S of 0.3 nM 
(Supplementary Table 1). No sub-micro molar inhibition was detected on any other of the tested cathepsins (Cat 
L, B, K, and F) with the exception of Cat V with apparent IC50 of 700 nM. In addition, RO5459072 showed ≤30% 
inhibition on a diversity panel consisting of nearly 100 receptor binding and enzymatic assays at 10 µM concen-
tration (not shown). The ability of RO5459072 to inhibit Cat-S in cells was tested with the lip10 accumulation 
assay in human purified B-cells from whole blood and a potent induction of lip10 was determined with EC50 of 
15.8 nM (Supplementary Figure 1A). Due to the high affinity and formation of a covalent bond between the nitrile 
warhead of RO5459072 and the catalytic cystein residue of Cat-S, the binding of the inhibitor is irreversible on the 
time scale of in vitro kinetic experiments. Thus, depletion of the concentrations of free inhibitor and free enzyme 
upon formation of the covalent complex need to be accounted for during quantitative analysis of the data using 
the Morrison equation. A value of Ki = 66 ± 25 pM was calculated for the inhibitor RO5459072 (Supplementary 
Figure 1B–D). The acute pharmacodynamic effect of RO5459072 in vivo was tested after oral gavage of doses from 
0.1–100 mg/kg. Splenic induction of p10 was used as a measure of enzyme inhibition. A strong p10 up-regula-
tion was detected with maximal induction at low doses of 1 mg/kg corresponding to a plasma concentration of 
the inhibitor of 17 nM (Supplementary Figure 1E). Oral administration of RO5459072 by food admix (262 mg/
kg of food) to female MRL-(Fas)lpr mice resulted in an exposure dose of 30 mg/kg and stable plasma levels 
of RO5459072 at 400–600 ng/ml over a period of 8 weeks. Mean plasma concentrations (SD) were 172 ± 58.4, 
648 ± 142 and 2660 ± 575 ng/ml at 3, 10 and 30 mg/kg/day respectively. This was associated with a robust p10 
fragment accumulation in the spleen (Supplementary Figure 1E). In summary, RO5459072 is a specific small 
molecule Cat-S inhibitor with favorable pharmacodynamic and pharmacokinetic profiles to efficiently block 
Cat-S over prolonged periods of time in MRL-(Fas)lpr mice.
Cathepsin S inhibition attenuates systemic autoimmunity in MRL-(Fas)lpr mice. To compare the 
potency of Cat-S inhibition with RO5459072 and MMF to suppress autoimmune disease we treated 11 week old 
nephritic MRL-(Fas)lpr mice with either drug or vehicle for 8 weeks. Both drugs suppressed CD11c+/CD11b+/
MHCII+ antigen-presenting cells in spleens of female MRL-(Fas)lpr mice but only RO5459072 suppressed 
CD11c+/F4/80+/MHCII+ cells (Fig. 1A). As a consequence, Cat-S inhibition (but not MMF) dose-dependently 
suppressed spleen plasma cells (FACS gating strategies for different spleen cells were illustrated in Supplementary 
Figure 2) and plasma IgG levels and IgG isotypes (Fig. 1B,C and Supplementary Figure 3). The highest dose 
of RO5459072 suppressed plasma levels of antinuclear antibodies, whereby the homogenous nuclear staining 
was indicative of dsDNA antibodies, which was further confirmed by ELISA (Fig. 1E,F). The highest dose of 
RO5459072 was particularly potent to suppress plasma dsDNA IgG levels below baseline (Fig. 1F). Consistent 
with its role in MHC-II antigen presentation-dependent immunoglobulin class switch, Cat-S inhibition did not 
affect total levels of IgM or dsDNA IgM (Fig. 1D and G). In contrast, MMF suppressed plasma IgM levels below 
baseline (Fig. 1D). Thus, therapeutic Cat-S inhibition suppresses antigen-presenting cells and downstream sys-
temic autoimmunity in MRL-(Fas)lpr mice. MMF does not reduce IgG autoantibodies but suppresses plasma IgM 
in MRL-(Fas)lpr mice.
Cathepsin S inhibition versus MMF in an animal model of lupus nephritis. To assess the impact 
of Cat-S inhibition and MMF treatment on autoimmune tissue injury we next examined lupus nephritis-like 
immune complex disease in MRL-(Fas)lpr mice. RO5459072 dose-dependently reduced the activity and chronic-
ity scores of nephritis, with the highest dose being even more efficacious than MMF therapy (Fig. 2). This was 
illustrated by less complement C3 deposits, diffuse proliferative glomerular lesions and glomerulosclerosis 
(Fig. 2A–D left and Supplementary Figure 4). Consistently, both drugs improved the integrity of the glomerular 
vasculature as illustrated by CD31 staining with the highest dose of RO5459072 demonstrating greater protection 
(Fig. 2D right-E). This finding was associated with a protective effect also on podocyte number, and proteinu-
ria, the latter being particularly evident at the highest dose of RO5459072 (Fig. 3A–C). It is of note that, Cat-S 
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inhibition had a remarkable early effect on proteinuria as compared to MMF (Fig. 3C). Blood urea nitrogen 
(BUN) was used as a marker of renal excretory function. All drugs prevented the progressive increase over time 
seen with vehicle treatment (Fig. 3D). In conclusion, high dose Cat-S inhibition is more potent than MMF to 
rapidly control lupus nephritis in MRL-(Fas)lpr mice.
Figure 1. Dose-dependent effects of cathepsin S-inhibition on systemic autoimmunity. From mice of all groups 
spleen cell suspensions were prepared for flow cytometry using specific antibodies that identify activated 
(MHC+) antigen-presenting cells, i.e. dendritic cells, macrophages, B cells (A) and plasma cells (B). Plasma 
levels of total IgG (C) and IgM (D) were determined by ELISA at 14 days intervals starting from week 11. 
(E) ANA staining patterns on Hep2 human epithelial cells for plasma, derived from mice of all groups at the 
end of the study at 1:200 dilution. The respective nuclear DAPI staining is shown in blue colour below (scale 
25 µm). Plasma levels of anti-dsDNA IgG (F) and IgM (G) antibodies were also determined by ELISA. Data are 
expressed as means ± SEM (n = 8 to 10 in each treatment group). *p < 0.05, **p < 0.01, ***p < 0.001 versus 
vehicle group. #p < 0.05, ###p < 0.001 base line values versus week 19 values.
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Cathepsin S inhibition and MMF suppress intrarenal inflammation. In lupus nephritis, intrarenal 
inflammation is a downstream event of systemic autoimmunity and immune complex disease22. Both drugs sup-
pressed intrarenal mRNA expression of IL-6, MCP-1/CCL2, RANTES/CCL5, and CXCL2, while that of TNF-α, 
IFN-γ, and SDF-1/CXCL12 remained unaffected (Supplementary Figure 5A and B). A similar consistent effect 
was noted on intrarenal expression of the vascular adhesion molecules I-CAM and V-CAM (Supplementary 
Figure 5C). Flow cytometry of kidneys from mice of all groups revealed that RO5459072 suppressed CD11c+/
Figure 2. Cathepsin S inhibition is more potent than MMF in suppressing kidney pathology. (A) Kidney 
sections of 19 week old MRL-(Fas)lpr mice of all groups were stained with periodic acid-schiff (PAS). The lupus 
nephritis disease activity index (A, score ranging from 0 to 24), and the lupus nephritis chronicity index score 
(C, ranging from 0 to 12) were determined as markers of kidney damage in lupus nephritis. Representative PAS 
staining kidney sections and immunofluorescence stainings for the endothelial cell marker CD31 were shown 
at an original magnification of x400 (scale 25 µm) (D). The quantitative analysis of glomerular complement C3 
positivity (B) and CD31 positivity (E) are shown. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, 
***p < 0.001 versus vehicle group.
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Figure 3. Cathepsin S inhibition has a rapid potent effect on albuminuria. Kidney sections of 19 week old 
MRL-(Fas)lpr mice of all groups were stained for WT1 and nephrin to quantify podocytes per glomerular cross 
section (A). Representative images are shown in (B) at an original magnification of x400 (scale 25 µm). Urinary 
albumin/creatinine (A/C) ratio was determined every 2 weeks and is expressed at logarithmic scale (C). Note 
that the highest dose of RO5459072 reduced A/C ratio quickly at 2 log scales more than MMF. Blood urea 
nitrogen (BUN) levels were determined at the same time points. Note the linear increae of BUN with time in 
vehicle-treated mice, while all treatments significantly reduced BUN (D). Data are expressed as means ± SEM 
(n = 8 to 10 in each treatment group). *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle group. #p < 0.05 base 
line values versus week 19 values.
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F4/80+/MHCII+, CD11c+/CD11b+/Ly6c+ and CD11b+/CD103+/CD86+ mononuclear phagocytes and 
CD45+/CD3+/CD8+, CD45+/CD3+/CD4+ and CD3+/CD4−/CD8− T cells (Supplementary Figure 6, gat-
ing strategies were illustrated in Supplementary Figure 7). The impaired lymphocyte recruitment to the kidney 
was also obvious from CD3 immunostaining (Supplementary Figure 4B and C right). The effect was comparable 
to that of MMF for most cell populations. Thus, Cat-S and MMF both suppress intrarenal inflammation.
Late onset of Cat-S inhibition still elicits therapeutic effects in experimental lupus nephri-
tis. To further assess the potency of Cat-S inhibition to control advanced lupus nephritis we performed iden-
tical experiments with the highest dose of RO5459072 and MMF, which were not initiated before week 15 of 
age and continued for only 4 weeks and terminated again at week 19. Very late treatment with RO5459072 also 
significantly suppressed plasma IgG and its isotypes and anti-dsDNA IgG below baseline, while MMF had no 
effect (Supplementary Figure 8A–D). MMF treatment showed a trend toward lower plasma IgM levels and did 
not affect anti-dsDNA IgM as seen upon early treatment (Supplementary Figure 8E and F). RO5459072 and 
MMF both significantly reduced proteinuria and BUN at week 19 compared to control mice (Supplementary 
Figure 9A,B). However, very late treatment had a limited effect on the histopathological parameters of lupus 
nephritis. Only RO5459072 significantly reduced the disease activity index and both drugs failed to significantly 
suppress the disease chronicity index (Supplementary Figure 9C–E).
Cathepsin S induces peripheral pathomechanisms on glomerular endothelial cells via 
protease-activated receptor-2 in vitro and in MRL-(Fas)lpr mice. Cat-S is known to have extra-
cellular protease activity, e.g. by activating PAR-2 on neuronal cells18, 20. To test for a similar function on renal 
endothelial cells we used recombinant Cat-S to stimulate primary murine glomerular endothelial cells (GEnC) 
and neutralized PAR-2 either with PAR-2-specific siRNA or a PAR-2 antagonist. A combination of Cat-S with LPS 
or interferon-γ induced detachment of annexin V/PI+ GEnC from the culture dish, which was entirely prevented 
by either PAR-2-specific siRNA or the PAR-2 antagonist FSLLRY amide (Fig. 4A and B). The beneficial effects 
of treatments were futher confirmed by flow cytometry using annexin V and PI staining (Fig. 4B). To test, if this 
cytotoxic mechanism also operates in MRL-(Fas)lpr mice, we intravenously injected 12 week old female MRL-
(Fas)lpr mice with recombinant Cat-S and assessed albuminuria and the glomerular ultrastructure by transmis-
sion electron microscopy (TEM). Cat-S induced albuminuria within 30 minutes after injection (Fig. 4C), which 
was associated with a diffuse swelling of the cytoplasm of the endothelial cells within glomerular capillaries lead-
ing to partial obstruction of the capillary lumen at 24 h (Fig. 4D). Endothelial cells lost their typical fenestrated 
appearance, but podocyte ultrastructure was preserved (Fig. 4D). The Cat-S inhibitor RO5459072 as well as the 
PAR-2 inhibitor GB83 completely prevented albuminuria and endothelial cell injury (Fig. 4C,D). In summary, 
Cat-S induces specifically endothelial cell injury via PAR-2 in vitro and in vivo.
Human neutrophils and monocytes release cathepsin-S upon stimulation. What is the source of 
extracellular Cat-S? To address this question we stimulated isolated human neutrophils in-vitro, using different 
ligands for TLR7 agonist, TLR9 agonist, IFN-γ, TNF-α and PMA. After 3 h of incubation, cell culture supernatents 
were analysed for Cat-S levels by ELISA. All reagents significantly increased the release of Cat-S (Fig. 5A and C). 
Similar results were obtained with human PBMCs (Fig. 5B,C). Thus, activated neutrophils and monocytes are a 
source of extracellular Cat-S.
Cathepsin-S plasma levels in patients with systemic lupus erythematosus and intrarenal 
expression in lupus nephritis. To validate these findings in human lupus we first quantified Cat-S lev-
els in plasma samples of patients with SLE. The patient characteristics are shown in Table 1. SLE patients had 
significantly higher plasma levels of Cat-S compared to healthy controls but there was no correlation of plasma 
Cat-S levels with SLE disease activity (Fig. 6A–C). Cat-S was also significantly increased in ISN-RPS classifica-
tion based positive lupus nephritis patients and CKD patients compared to healthy controls (Supplementary 
Figure 10A–D). Next we assessed intrarenal expression of Cat-S in lupus nephritis. We used immunostaining for 
Cat-S and the macrophage marker CD68 on serial sections of kidney biopsies from patients with proliferative 
lupus nephritis. Within glomeruli Cat-S staining was most prominent in single cells within the glomerular tuft, 
which co-localized with CD68 positivity (Fig. 6D). Glomeruli that lacked CD68+ cell infiltrates hardly showed 
any Cat-S positivity (Supplementary Figure 10E). Tubules stained positive for Cat-S in all sections (Fig. 6D and 
Supplementary Figure 10E), as previously reported also from normal kidneys23. Further to confirm the associa-
tion of increased Cat-S levels in MRL-(Fas)lpr mice, we stained kidney sections of MRL-(Fas)lpr mice of different 
age groups for Cat-S. Increased expression of Cat-S levels in kidneys affected with lupus nephritis were found spe-
cifically co-localized to macrophages positive for Mac-2 marker, whereas kidneys of MRL-wt mice were negative 
for both Mac-2 and Cat-S (Fig. 6E). In conclusion, both mouse and human SLE is associated with elevated levels 
of Cat-S and in lupus nephritis infiltrating macrophages are a source of intrarenal Cat-S expression.
Discussion
The essential roles of Cat-S in MHC-II processing and in PAR-2-mediated vascular injury prompted us to 
speculate that therapeutic Cat-S inhibition could elicit a dual effect on autoimmune vascular disease that 
is more selective and superior to conventional immunosuppressive drugs. Our data validate this concept for 
RO5459072-mediated Cat-S inhibition in lupus nephritis of MRL-(Fas)lpr mice. In addition, selective Cat-S inhi-
bition avoids the unspecific immunosuppressive effect of MMF on plasma IgM that are important for first line 
host defense. However, Cat-S inhibition will still impair MHC-II-driven IgG responses needed for host defense. 
As such, some effect on host defense can also not be avoided with Cat-S inhibition. We had previously shown that 
another, closely related Cat-S antagonist, RO5451111, can suppress the priming of autoreactive T and B cells and 
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Figure 4. Cathepsin S activates glomerular endothelial cells via protease-activated receptor(PAR)-2. Mouse 
glomerular endothelial cells were transiently transfected with control siRNA (scrambled) or siRNA specific for 
PAR-2. Endothelial cell activation with lipopolysaccharide (LPS) or interferon-gamma (IFN-γ) plus different 
concentrations of Cat-S induced detachment of the cells from the culture dish (A). Flow cytometry of the 
detached cells identified them to be annexin V/propidium iodide (PI) positive (B). Cells transfected with 
PAR-2 siRNA or the PAR-2 inhibitory peptide FSLLRY amide lacked this effect. Female MRL-(Fas)lpr mice 
were intravenously injected with 10 µg of recombinant Cat-S and albuminuria was determined 30 min later (C). 
Note that the Cat-S-induced albuminuria was entirely blocked by the Cat-S inhibitor RO5459072 or the PAR-2 
inhibiting peptide GB83. After 24 h kidneys were harvested for an ultrastructural analysis of glomerular 
capillaries. Representative images are shown in (D). Note that Cat-S injection induced a massive swelling of 
the glomerular endothelial cells, with loss of the endothelial fenestrations and obliteration of the vascular 
lumen. Focal podocyte foot process effacement was also present. In contrast RO5459074 and GB83 completely 
prevented these abnormalities (scale 2 µm). Data in (C) are expressed as means ± SEM (n = 3 in each  
group). ***p < 0.001 versus PBS group.
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Figure 5. Activated neutrophils and monocytes secrete cathepsin S. Neutrophils (A) and PBMCs (B) were 
isolated from human blood and exposed to phorbol myristate acetate (PMA), IFN-γ, the TLR9 ligand CpG-
DNA, the TLR7 ligand imiquimod, and TNF-α as indicated. Two hours later Cat-S secretion was quantified 
in the supernatants by ELISA. The cells were also stained with a FITC-labeled Cat-S antibody (green signal) 
and DAPI (blue signal) (C) (scale 25 µm). Note that all stimuli induce Cat-S expression and secretion in both 
cell types. Data are means ± SEM from 3 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 versus 
media control.
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germinal center formation in MRL-(Fas)lpr mice17, 23. The present study further explores this novel therapeutic 
concept in five different ways:
First, we tested the bioactivity of the additional Cat S inhibitor RO5459072 and found that it elicits a clear 
dose-dependent immunomodulatory effect on almost each of the analyzed parameters of systemic autoimmune 
disease and autoimmune tissue injury in MRL-(Fas)lpr mice. This consistent dose-dependency is in support of a 
specific pharmacological inhibition of the Cat-S-dependent pathophysiology in systemic autoimmunity.
Second, we compared the therapeutic efficacy of the Cat-S inhibitor RO5459072 with MMF at a dose proven 
to efficiently control SLE and lupus nephritis of MRL-(Fas)lpr mice24–26. MMF potently suppressed all aspects of 
SLE and lupus nephritis in MRL-(Fas)lpr mice, although a relatively poor effect on dsDNA IgG levels was noted. 
We found Cat-S inhibition with 30 mg/kg RO5459072 from week 11–19 to be more potent than MMF in con-
trolling spleen macrophage activation, plasma cell expansion, hypergammaglobulinemia, and anti-dsDNA-IgG 
production as well as the activity and chronicity indices of lupus nephritis. Most importantly, unlike MMF Cat-S 
inhibition did not suppress plasma IgM, which are an important component for the immediate innate host 
defense against pathogens27. This selective immunosuppressive effect sparing IgM levels might translate into a 
lower risk for treatment-related infections that is still a problem with currently used therapeutic regimen for 
autoimmune diseases2.
Third, we compared delayed versus very late onset of treatment for both drugs in order to evaluate the thera-
peutic window in autoimmune disease. Very late onset of 30 mg/kg RO5459072 was still more potent than MMF 
to effectively suppress hypergammaglobulinemia and anti-dsDNA production, albuminuria, and lupus nephritis 
disease activity. However, the capacity of both drugs to suppress lupus nephritis chronicity was much lower than 
with the earlier start of the treatment. This finding is in line with the general concept of “the earlier-the better” 
that applies for autoimmune and non-autoimmune forms of progressive CKD28. Indeed, at more advanced stages 
of the disease process the vasoprotective effect of Cat-S inhibition may be less pronounced than at earlier stages.
Fourth, we explored the capacity of RO5459072 to block Cat-S-mediated PAR-2 activation and injury of 
endothelial cells in vitro and in MRL-(Fas)lpr mice. PAR-2 suppression specifically impaired the Cat-S-driven 
alteration of glomerular endothelial cells that were preactivated with the TLR4 agonist LPS or IFN-γ. Cat-S or 
PAR-2 inhibition both prevented Cat-S-induced injury to the glomerular filtration barrier, i.e. endothelial cell 
injury and barrier dysfunction (albuminuria). These data are consistent with our recent findings in diabetic mice 
Control n = 23 SLE n = 50
Female, n (%) 17 (74) 41 (82)
Age (years) 42.3 ± 5.6 45.8 ± 1.8
SLEDAI score >4, n (%) — 50 (100)
SLICC/ACR damage index >1, n (%) — 33 (66)
Leukopenia, n (%) — 14 (28)
Thrombocytopenia, n (%) — 14 (28)
Fatigue, n (%) — 39 (78)
Arthralgia, n (%) — 45 (90)
Jaccoud’s arthropathy, n (%) — 20 (40)
Malar rash, n (%) — 34 (68)
Pericarditis, n (%) — 13 (26)
Pleuritis, n (%) — 14 (28)
Venous thrombosis, n (%) — 10 (20)
Lupus nephritis, n (%) — 24 (48)
 ISN/RPS class I, n (% of all LN) — 1 (4)
 ISN/RPS class II, n (% of all LN) — 4 (17)
 ISN/RPS class III, n (% of all LN) — 5 (21)
 ISN/RPS class IV, n (% of all LN) — 14 (58)
CKD, n (%) — 28 (56)
 CKD 1, n (% of all CKD) — 19 (68)
 CKD 2, n (% of all CKD) — 1 (4)
 CKD 3, n (% of all CKD) — 5 (17)
 CKD 4, n (% of all CKD) — 2 (7)
 CKD 5, n (% of all CKD) — 1 (4)
Hemolytic anemia, n (%) — 10 (20)
Antinuclear antibodies, n (%) — 47 (94)
Anti-dsDNA IgG, n (%) — 31 (62)
Table 1. Clinical characteristics of SLE patients and healthy control subjects. SLEDAI: Systemic lupus 
erythematosus activity index, SLICC/ACR: Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology, CKD: Chronic kidney disease.
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Figure 6. Cathepsin S in human SLE and lupus nephritis. (A) Cat-S plasma levels were determined in patients 
with systemic lupus erythematosus (SLE) and healthy controls by ELISA. The patient characteristics are listed in 
Table 1. ***p < 0.001 versus healthy controls. (B,C) In SLE patients Cat-S plasma levels were not correlated with 
the respective SLE disease activity index (SLEDAI). (D) Dual immunostaining for Cat-S and the macrophage 
marker CD68 of human kidney biopsies showed double positivity in single cells within the glomerular tuft. Cat-S 
positivity was also noted in CD68 negative tubular epithelial cells. Representative images of two different renal 
biopsies (class IV lupus nephritis) are shown at the indicated scale 100 µm. (E) Dual fluoresence staining for Mac-2 
and Cat-S in kidneys of MRL-(Fas)lpr mice of different age groups compared to MRL-wt (scale 25 µm).
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with Cat-S-mediated endothelial dysfunction19 and are in line with other reports on Cat-S-specific PAR-2 acti-
vation18, 20.
Finally, we assessed the expression of Cat-S in human SLE and lupus nephritis and identified activated neu-
trophils and macrophages as a source of circulating Cat-S. While neutrophils contribute to disease activity mostly 
via NET formation outside the kidney29, activated macrophages also recruit inside the kidney and contribute to 
autoimmune tissue injury30–34. SLE patients displayed higher plasma levels of Cat-S but independent from disease 
activity. The same was observed for patients with rheumatoid arthritis35, which may relate to a low threshold of 
Cat-S induction in diseased individuals. However, increased plasma levels of Cat-S have been observed in lupus 
patients with nervous system disorders36 or numerous patient cohorts with other chronic disease entities and 
were shown to imply higher mortality37, 38. This finding may be clinically important because the presence of lupus 
nephritis is also associated with poor overall survival39.
In summary, Cat-S has a dual effect in autoimmune disease. First, Cat-S is a non-redundant element of 
MHC-II-mediated autoantigen presentation and second, Cat-S secreted, e.g. by activated immune cells, promotes 
PAR-2-driven endothelial injury in organs affected by autoimmune tissue inflammation. As such initiating Cat-S 
inhibition even after the onset of clinically apparent autoimmune disease not only specifically suppresses the 
central immunological pathomechanism shared by all autoimmune diseases17, i.e. MHC-II-mediated autoantigen 
presentation but also protects the peripheral vascular interface and thereby suppresses leukocyte recruitment, 
tissue inflammation and remodeling of organs affected by autoimmune injury, especially when treatment is ini-
tiated early. The highly specific blockade of MHC-II processing with Cat-S inhibition avoids the broad immuno-
suppressive effect of nonspecific immunosuppressant drugs like MMF that also suppress plasma IgM, which are 
essential for immediate host defense. We therefore conclude that Cat-S inhibition may represent a next generation 
immunomodulatory strategy for all types of autoimmune diseases by combining highly specific neutralization 
of autoantigen-presentation with vasoprotective and anti-inflammatory effects, which can have potent additive 
effects especially when initiated early during the disease course.
Materials and Methods
In-vitro charecterization of the cathepsin S inhibitor RO5459072. RO5459072 was provided by 
F. Hoffmann-La Roche, Ltd., Basel, Switzerland. It is a competitive inhibitor of the active site of Cat-S and its 
nitrile function allows covalent reversible inhibition of Cat-S. The synthesis of RO5459072 has been described 
in WO 2010121918 and WO 2013068434. Recombinant cathepsins were produced in-house or were purchased 
from commercial vendors. Initial enzymatic assays to determine isoform-selectivity in vitro were performed as 
previously described21, 23. As the selectivity assays indicated Ki values for the interaction of RO5459072 with 
human Cat-S that were below the concentration of enzyme in the assays suggesting tight binding, we proceeded 
with a detailed kinetic analysis40, 49. For this the Cat-S-dependent hydrolysis of the fluorogenic substrate Z-Phe-
Arg-AMC (Sigma Aldrich) was followed at various inhibitor concentrations. The active fraction of Cat-S was 
detemined as 70% with a HPLC assay measuring modification of Cat-S with the covalent inhibitor LHVS. The 
buffer (100 mM potassium phosphate, 50 mM NaCl, 5 mM EDTA, 5 mM TCEP, pH 6) was thoroughly degassed 
prior to perfoming measurements to prevent oxidation of the catalytic cystein residue by dissolved oxygen. For 
the Ki-determination the substrate was employed at 10 µM = KM. All kinetic measurements were performad on 
a SFM-3000 stopped-flow instrument (Bio-Logic Science Instruments) and data were analyzed with GraphPad 
Prism v5. RO5459072 did not show any signals regarding drug safety in extensive screening studies in mice, rats, 
monkeys and humans that preceeded the currently ongoing clinical trial (NCT01701985).
Mice and protocol for experimental SLE and lupus nephritis. Four-week-old female MRL-(Fas)lpr 
mice were purchased from Harlan Winkelmann (Borchen, Germany) and kept under pathogen-free conditions 
in a 12 hour light and dark cycle with free access to food and water. All animal experiments were performed in 
accordance with the European protection laws of animal welfare, and with approval by the local government 
authorities Regierung von Oberbayern (reference number: 55.2.1-54-2532.2-11-12). At 11 or 15 weeks of age only 
mice with proteinuria (Albustix, Bayer AG, Leverkusen, Germany) were randomized into five different groups 
(n = 10) receiving different medicated diets: Three groups were fed with chow mixed with either 3, 10 or 30 mg/
kg/day RO5459072, another group’s chow was mixed with 100 mg/kg/day mycophenolate mofetil (MMF), and 
one group received a standard diet (vehicle). The dose of MMF was chosen according to several studies reporting 
strong efficacy on SLE and lupus nephritis in MRL-(Fas)lpr mice24–26. Food intake was measured once weekly 
and was stable at approximately 5 g food per day throughout the study period with no significant difference of 
food intake or body weight between any of the groups. At the age of 19 weeks all mice were sacrificed by cervical 
dislocation. Blood and urine samples were collected at different time points as indicated. In other experiments 
7 week old female MRL-(Fas)lpr mice were randomized into three groups (n = 3) to receive a single intravenous 
injection of 10 µg sterile recombinant Cat-S and one group receiving vehicle (100 µl sterile PBS). One of the Cat-S 
groups was pretreated with 30 mg/kg/day RO5459072 starting one week prior to Cat-S injection; another group 
was pretreated with a total of four daily intra-peritoneal injections of the PAR-2 inhibitor GB83 (10 mg/kg).
Plasma samples were collected from mice during the feeding cycle on weeks 2, 4, 6 and 8 on a variable schedule 
of individuals after initiation of feeding with the drug-food admix on week 1. The levels in food were calculated 
to achieve doses of 3, 10 and 30 mg/kg/day. EDTA-treated plasma samples (29 per dose level) were frozen and 
subsequently analysed for the parent drug by HPLC-MS/MS. A column-trapping method (Phenonenex Luna C18 
and Thermo Hypersil Gold C8 HPLC columns eluted with formic acid/water/acetonitrile mixtures on a Waters 
Acquity HPLC system) was used to separate the drug which was quantified using a Sciex API4000 MS/MS. The 
analytical range was 10–10,000 ng/ml and a stable label internal standard was used. Urine samples were collected 
from all mice at baseline and after 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h. All experiments were performed according to 
German animal protection laws and had been approved by the local government authorities.
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Morphological evaluation. Kidney tissue samples were collected from all mice and fixed overnight in 4% 
buffered formalin. Subsequently the fixed tissue samples were embedded in paraffin and cut into 4 µm thick serial 
sections. Kidney paraffin sections were stained with periodic acid-Schiff (PAS) reaction using standardized proto-
cols as described41. Scoring of lupus nephritis activity and chronicity indices was performed according to human 
lupus nephritis42, 43. Methenamine silver staining was performed on paraffin embedded kidney sections and sem-
iquantitatively scored form 0–3 by a blinded observer. For immunostaining the following primary antibodies 
were used: anti-mouse CD3 (Abcam, Cambridge, UK), complement C3c (Biobyt Ltd, Cambridge, UK), CD31 
(Dianova GmbH, Hamburg, Germany), WT1 (Santa Cruz Biotechnology, Dallas, Texas) and nephrin (Acris 
Antibodies, San Diego, CA). The immunostaining for C3c and CD31 were analyzed using the ImageJ software by 
measuring positively stained area and dividing it by the total area of the glomerulus and reported as percentage of 
+ve area. Sections stained for WT1/nephrin and CD3 were evaluated by counting positive cells per glomerulus. 
All the morphometric analysis were carried out in a blinded fashion.
Biomarkers of renal function and autoantibody production. Urinary albumin/creatinine ratios were 
determined using the Mouse Albumin ELISA Quantitation set (Bethyl Laboratories, Montgomery, TX) and the 
Creatinine FS kit (DiaSys Diagnostic Systems, Holzheim, Germany)44. BUN levels were determined in plasma 
samples using a Urea FS kit (DiaSys Diagnostic Systems). Mouse IgM, IgG and its isotypes IgG1, IgG2a and IgG2b 
plasma levels were measured using ELISA Sets (Bethyl Laboratories) at a plasma dilution of 1:1,000 to 1:100,000. 
Double-stranded DNA IgG and IgM antibodies were quantified as described45. Briefly, 96 well Nunc-Immuno 
plates (Thermo Fisher Scientific, Roskilde, Denmark) were coated with poly-L-lysine (1:1 diluted with PBS) 
and incubated for two hours. After washing the plates, the plates were coated with 1 µg/ml mouse tail dsDNA 
sparing the wells for standards, which were coated with anti-mIgG and anti-mIgM (Bethyl Laboratories). The 
standard curve was fixed from purified mIgG and mIgM (Bethyl Laboratories). The plasma samples were diluted 
1:1,000 and added into the wells. After 1 h the assay was developed using HRP-labelled goat anti-mIgG and 
anti-mIgM and TMB substrate (BD Bioscience, San Diego, CA). Absorbance was measured at 450 nm using a 
Tecan Microplate Reader (Biotek, Winnoski, VT). Indirect immunofluorescence was used to quantify ANA in 
mouse plasma. 1:200 diluted mouse plasma was applied to slides covered with HEp-2 cells (Bio-Rad Laboratories, 
Redmond, WA, USA) as described43.
Transmission electron microscopy. Mouse kidney tissue was fixed in 2% paraformaldehyde/2% glutar-
aldehyde and 0.1M sodium phosphate buffer (pH 7.4) for 24 hours and processed as described19. Samples were 
analyzed with a 1200EX electron microscope (JEOL, Tokyo, Japan).
Immunohistochemistry in human renal biopsies. Renal biopsies from patients with active lupus 
nephritis were selected from the files of the Department of Pathology and Immunology, University Hospital 
of Geneva. Informed consent was obtained in all cases. The renal tissue was fixed in 4% PBS-buffered formalin 
and embedded in paraffin. For all biopsy specimens, standard analysis using light microscopy, immunofluores-
cence (with anti-IgA, G, M, and anti-complement C1q, C3, C4 and C5b-9 antibodies) and electron microscopy 
was performed. Scoring of lupus nephritis activity and chronicity indices was performed according to the ISN/
RPS 2003 classification46. For immunostaining, serial paraffin sections were stained with the primary antibodies 
anti-cathepsin S (polyclonal goat anti-human Cat-S, Abcam, Cambridge, UK) and anti-CD68 (DakoCytomation, 
Glostrup, Denmark), or double stained with anti-cathepsin S and anti-CD68 as previously reported19. 8 renal 
biopsies (2 class II, 2 class III, 3 class IV and 1 class V) were analyzed.
Cathepsin-S levels in SLE patients plasma samples. Plasma samples from Lupus patients listed in 
the Munich cohort of active SLE patients, as well as plasma samples form healthy controls were stored at −20 °C 
untill all the analyses were completed. Cat-S plasma levels were measured by using a commercially available Cat-S 
ELISA kit (R&D Systems, Minneapolis, MN, USA). All patients had given written informed consent.
Cell culture assays. GEnCs were suspended in 1 M nucleofection buffer mixed with siRNA to PAR-2 
(Ambion, Cat. AM16708) or scrambled siRNA as control (Cat. 4390843). Nucleofections were performed using a 
Lonza electroporation instrument and efficacy was measured by qRT-PCR. After transfection the cells were cul-
tured in RPMI medium containing 1% FCS and 1% PS. Another set of GEnCs were prestimulated with the PAR-2 
inhibitor (FSLLRY-amide) for 30 min. Once the cells adhered to the plates, they were plasma-fasted for 2 h in fresh 
incomplete RPMI medium and stimulated for 20 hours with LPS (0.5 µg/ml) or IFN-γ (1000 IU) in the presence 
of either 1 µg or 2 µg Cat-S, or left as unstimulated media controls. One group of GEnCs were not transfected but 
were prestimulated with the PAR-2 inhibitor (FSLLRY-amide) for 30 min before stimulation. Detached cells in 
the supernatant were counted using a scepter hand held automated cell counter (Millipore, Cat. PHCC00000, 
Billerica, MA, USA) and then stained with Annexin/PI (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) 
for flow cytometric analysis.
Human neutrophils were isolated from full blood samples of a healthy donor, who had given written informed 
consent, using a standard dextran sedimentation method followed by Lymphoprep (Stemcell Technologies, 
Cologne, Germany) density centrifugation. 0.5 × 106 or 5 × 106 neutrophils were suspended in 200 to 500 µl RPMI 
media and seeded into 8 well µ slides or 12 well plates (Ibidi, Martinsried, Germany). The cells were stimulated for 
3 h with phorbol 12-myristate 13-acetate (25 nM; PMA, Sigma-Aldrich, Steinheim, Germany), IFN-γ (1000 IU/
ml), imiquimod (5 µg/ml, Invivogen, San Diego, California), CpG DNA (25 µg/ml, Invivogen) or TNF-α (200 nM, 
Immunotools, Germany). A Cat-S ELISA (R&D Systems, Minneapolis, MN, USA) was used to quantify protein 
in the supernatant. Cells on 8 well µ slides were immunostained for Cat-S (Abcam).
For isolating human PBMCs full blood samples were collected from a healthy donor, as described above. 
The blood was diluted 1:1 with sterile PBS and layered on a Lymphoprep solution (Stemcell Technologies). By 
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subsequent density gradient centrifugation at 800 g for 30 min at room temperature PBMCs were separated 
from other blood components. The PBMCs were washed with RPMI medium and seeded at a concentration of 
0.5 × 106 or 1 × 106 cells/well in 12 well plates or on 8 well µ slides. The cells were stimulated with IFN-γ (1000 
IU/ml), imiquimod (5 µg/ml), CpG-DNA (25 µg/ml) or TNF-α (200 nM). After 2 hours the supernatant was col-
lected, Cat-S levels were measured by ELISA (R&D Systems) and the cells on the 8 well µ slides were double 
stained with FITC-anti-Cat-S (Abcam) and DAPI.
Pharmacodymamics of Cathepsin S inhibition by RO5459072 in human B-cells and mouse 
spleens in vivo. For the determination of in-vivo enzyme inhibition activity of Cat-S by RO5459072 BALB/c 
mice were used. After oral dosing of 0.1 mg/kg to 100 mg/kg of RO5459072, mice were sacrificed after 7 hours and 
spleens harvested. Invariant chain was quantified by western blot from mouse splenocyte supernatants loaded onto 
10% SDS-PAGE gel. Upon transfer onto a nitrocellulose membrane rabbit anti-CD74 (BD Biosciences) was used.
Human B-cells were isolated from whole blood using the Whole Blood CD19 Microbeads (Cat#130-090-880, 
Milteny) with the Whole Blood Column Kit (130-093-545, Milteny) according to the instruction leaflet. Isolated 
B-cells were adjusted to a cell density of 1 × 106 cells/ml in RPMI medium containing 10% FCS and 0.05 mM 
β-Mercaptoethanol (media and supplements are from Gibco). For each condition 100 µl of cell suspension was 
transferred into one well of a 96 well cell culture plate, respectively. For detection of p10, cells were treated with 
different concentrations of RO5459072 for 16 h in a cell culture incubator (37 °C; 5% CO2). Afterwards cells were 
lysed by adding 100 µl 2x NP-40 lysis buffer (20 mM Tris pH 8.0; 137 mM NaCl; 10% glycerol; 1% NP-40; 2 mM 
EDTA) containing HALT Protease inhibitor (Cat#78429, Pierce) for 30 min on ice. Before detection of accumu-
lated p10-MHC-II complexes, interfering Ii-MHC-II associates were removed from the cell lysates. Therefore the 
cell lysates were incubated twice for 2 h at 4 °C on two different ELISA plates (Maxisorp/NUNC) which were pre-
viously coated with CD74–18/3 (5 µg/ml/overnight) and subsequently blocked with blocking buffer (50 mM Tris, 
140 mM NaCl, 5 mM EDTA, 0.05% NP40 and 0.25% gelantine pH 7.4) for 1 h at 37 °C. The CD74-18/3 antibody 
detects uncleaved invariant chain MHC-II complexes only. Afterwards p10-MHC-II complexes were analyzed 
by ELISA. For this purpose black Maxisorp plates from NUNC have been coated o/n with PIN.1 (5 µg/ml) from 
abcam (Cat#ab22603). The next day plates were blocked with blocking buffer for 1 h at 37 °C. Lysates containing 
25,000 B-cells per condition were transferred to each well of the ELISA plate respectively and incubated together 
with the secondary antibody CD74-3/5-Biotin (15 ng/ml) o/n at 4 °C on a shaker. For signal amplification samples 
were incubated for 30 min with High Sensitive Streptavidin-HRP, 50 ng/ml (Cat#21134, Pierce). The amount of 
p10 was detected after 30 min of incubation with the QuantaBluTM Fluorogenic Substrate (Cat#15162, Pierce) 
at 325 nm excitation and 420 nm emission. In between each procedure of the ELISA assay the plates were washed 
twice with PBS−/− containing 0.05% TWEEN-20.
Flow cytometry. Whole kidneys and tissue from 1/3 of a spleen were processed to single cell suspensions 
and stained with the following antibodies purchased from BD Bioscience (San Diego, CA, USA): anti-mouse 
CD3e-FITC, Ly6c-FITC, CD11b-PE, CD11c-PE, CD45-PE, k Light Chain-PE, CD8a-PerCP, CD4-APC, 
CD11b-APC, CD138-APC, CD86-FITC. Also used for staining were anti-mouse MHC-II-FITC and CD103-APC 
(both from eBioscience, San Diego, CA) and F4/80-APC from Bio-Rad (Raleigh, NC, USA). Detached GEnCs 
were stained with annexin/PI (Miltenyi Biotec, Germany). The FACSCalibur flow cytometer was used for acquir-
ing the cells and analysis was done using the CellQuest software.
Quantitative Real-time PCR. Total RNA was isolated from kidney tissue using PureLink 
RNA Mini Kit (Invitrogen, Calsbad, CA). The RNA’s quality and concentration was measured with a 
NanoDrop (Thermo Scientific, NanoDrop products, Wilmington, DE) and later cDNA was synthe-
sized using SuperScript II Reverse Transcriptase (Invitrogen). Gene expression rates were determined 
by quantitative real-time PCR applying the SYBR Green Dye detection system on the LightCycler 480 
(Roche Diagnostics, Mannheim, Germany). The following primers were purchased from Metabion, 
Martinsried, Germany: Ccl2 (R: ATTGGGATCATCTTGCTGGT and F: CCTGCTGTTCACAGTTGCC), 
C cl5  (R :  GTGC C CAC GTCAAGGAGTAT and F:  C CACT TCT TCTCTGGGT TGG),  Cxcl2 
( R :  T C C AG G T C AG T TAG C C T T G C  a n d  F :  C G G T C A A A A AG T T T G C C T T G ) ,  I l 6  ( R : 
A C C A G A G G A A AT T T T C A ATA G G C  a n d  F :  T G AT G C A C T T G C A G A A A A C A ) ,  I f n - γ 
(R :  TGAGCTCAT TGAATGCT TGG and F :  ACAGCAAGGC GAAAAAGGAT) ,  Tnf-α  (R : 
TAG AC A AG G TAC A AC C C ATC G G  and  F :  AG C C TC T TC TC AT TC C TG C T ) ,  Vc am - 1  ( R : 
ACT TGTGCAGC CAC CTGAGATC and  F :  GCTATGAGGATGGAAGACTCTGG),  Ic am-1 
( R :  A AC AG T T C AC C T G C AC G G AC  an d  F :  G T C AC C G T T G T G AT C C C T G ) ,  SDF- 1  ( R : 
TTTCAGATGCTTGACGTTGG and F: GCGCTCTGCATCAGTGAC). For every gene RT- and water samples 
were used as negative controls as well as 18S rRNA acting as an endogenous control47, 48. For analysis the compar-
ative threshold cycle (ΔΔCp) method was used.
Statistical analysis. All the data were first checked for Gaussian distribution using Kolmogorov-Smirnov 
test. Normally distributed data were analyzed by ordinary one-way ANOVA followed by Dunnett’s multiple 
comparisons as post hoc test, while data not showing a Gaussian distribution were analysed by nonparametric 
ANOVA (Kruskal-Wallis test) followed by Dunn’s multiple comparisons as post hoc test. Comparisons of end-
point time-points to baseline time-points were performed using a Student t-test. P < 0.05 was considered statis-
tically significant. Human samples were analysed for the Gaussian distribution applying D’Agostino-Pearson test 
and Cathepsin-S levels between healthy and SLE samples were analysed using nonparametric t-test. Correlation 
co-efficient “r” was calculated using Spearman nonparametric correlation for the data set of Cathepsin-S levels 
vs SLEDAI or SLICC. Statistics were calculated using the software GraphPad Prism (version 5; GraphPad, San 
Diego, CA, USA).
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